Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 53

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 53
---
. Attachment
to Tb161 results in potentially curative treatment by sustained tumor regression and a significant increase in median survival time. PSA-mAb
is at pre-clinical stage. A Phase I therapeutic trial in Australia with RAD402, is anticipated to start after Ethics Committee approval
that we expect to request by the end of 2025. RAD402 targets prostate cancer.

PSA is a 33 kD6 protein synthesized
in the epithelial cells of the prostate gland. It is an enzyme or protease that belongs to the subgroup of kallikreins and has a function
in facilitating sperm motility. PSA is present in small quantities in the serum of men with healthy prostates and is often elevated in
the presence of prostate cancer, albeit it is not uniquely an indicator of prostate cancer as it may also be elevated in the non-cancerous
conditions of prostatitis or benign prostatic hyperplasia.

PTPµ (PTPmu)

PTPµ (PTPmu) is a
peptide molecule biomarker, invented by Dr Susann Brady-Kalnay at Case Western Reserve University in Ohio. This molecule is highly
specific targeting agent for the detection, imaging and treatment of tumors. When combined with low level radiation, the PTPµ
biomarker functions as a highly specific PET imaging agent. When combined with high energy radiation, the PTPµ biomarker works
as a radiopharmaceutical theranostic to destroy tumors. In therapeutic mode, the biomarker labels tumor cells far away from the main
tumor mass, achieving specific recognition of the full extent of an invasive tumor. The biomarker recognizes PTPµ in multiple
tumor types including brain and gynecological tumors. Currently in pre-clinical stage, initial trial activity will focus on
glioblastoma. Our assets RAD601 and RAD602 are currently in the pre-clinical state.

Radiopharm Ventures LLC

Radiopharm Ventures will initially
focus on developing at least four therapeutic products. The first potential therapeutic candidate is a humanized immunoglobulin G (IgG)
antibody, also known as B7H3 mAb, against tumor-specific antigen B7-H3, also known as CD276, which is highly expressed in several common
tumors but not in healthy cells. B7H3 mAb is intended to be developed as a therapeutic assets targeting multiple solid tumors such as
prostate, lung, hepatocellular, carcinoma